264 results about "Proteinoid" patented technology

The present disclosure provides proteins useful for preventing, treating, suppressing and / or eliminating infestations and infections of plants by various phytopathogenic pests, as well as formulations comprising such proteins, polynucleotides encoding such proteins, organisms expressing such proteins, and methods of using such proteins, formulations, polynucleotides and organisms in agriculture and other fields of endeavor.

Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.

The invention belongs to the technical field of microorganisms, discloses a strain of pseudomonas putida and application of the strain of pseudomonas putida as fish probiotics, and particularly discloses a strain of pseudomonas putida. The invention provides a symbiotic pseudomonas putida CD separated from fish, and the strain has relatively strong fat utilization capability, can generate a plurality of beneficial extracellular metabolites, can promote metabolism of fish lipids, carbohydrates and proteins and weight gain, and also can improve the iron content and hemoglobin content in fish tissues. The pseudomonas putida strain CD disclosed by the invention has good biological safety, and has a wide development prospect in the aspect of application as fish probiotics.

This disclosure relates methods for expanding γδ T cells. More specifically, the disclosure relates to methods of expanding γδ T cells that have an eliminated or reduced expression of endogenous MHC Class I molecules, by expressing a single-chain fusion HLA Class I protein. In some embodiments, the endogenous B2M gene of the γδ T cells is disrupted. In some embodiments, the single-chain fusion HLA Class I protein includes at least a portion of B2M protein and at least a portion of HLA-E heavy chain.

The invention discloses a TLP1-like gene molecular marker related to cotton verticillium wilt resistance and application of the TLP1-like gene molecular marker, and belongs to the field of biotechnology application. The promoter of the TLP1 protein gene TLP1-like has two haplotypes, the promoter sequence of the haplotype 1 is SEQ ID NO.5, and the genomic sequence of the haplotype 2 is SEQ ID NO.6. The invention also discloses a method for preparing the TLP1 protein gene TLP1-like promoter of the TLP1 protein gene TLP1-like promoter of the TLP1 protein gene. Compared with the haplotype 1, the haplotype 2 has an SV insertion of 2623 bp at a-899 bp position of an ATG upstream promoter region of a TLP1-like gene, so that the expression quantity of the TLP1-like gene is reduced. An InDel functional marker capable of remarkably distinguishing the haplotype 1 and the haplotype 2 is further developed. Compared with the haplotype 1, the haplotype 2 has a remarkable advantage in the aspect of improving the verticillium wilt resistance of the cotton, and the silent haplotype 1 cotton plant TLP1-like remarkably improves the resistance of the cotton to verticillium dahliae. The haplotype 2 has important effects and application prospects in screening cotton disease-resistant materials and cultivating cotton high-resistance varieties.

Disclosed herein are cells and populations of cells comprising a genome in which the B2M gene has been edited to eliminate surface expression of MHC Class I protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.

Plasma kallikrein binding proteins and methods of using such proteins are described.

The invention relates to the technical field of plant genetic engineering, and particularly provides cloning of a GbGELP25D gene of gossypium barbadense and application of the GbGELP25D gene of gossypium barbadense. According to the invention, the GbGELP25D gene with a full length of 1092 bp is cloned from the sea island cotton variety Xinhai No. 7 for the first time, and the gene encodes a secretory lipase protein with a signal peptide and is positioned in an extracellular gap. Through bioinformatics analysis, phylogenetic classification, protein structure modeling and signal peptide function verification, it is clear that the gene belongs to a plant GELP family. Furthermore, a virus-induced gene silencing technology is utilized to prove that the silent GbGELP25D can obviously enhance the resistance of cotton to verticillium wilt, and the mechanism of the silent GbGELP25D is closely related to activation of ethylene synthesis and signal channels and induction of expression of disease-resistant related genes. The resistance gene provided by the invention enriches gene resources of cotton verticillium wilt resistance breeding, and has important theoretical significance and application value.

The invention relates generally to CD19 antibodies and antigen-binding fragments thereof, to chimeric receptors comprising the same, and to cells configured to express such proteins. The invention also relates to methods of using such antibodies, chimeric receptors, and cells in the treatment of various diseases, including cancer and autoimmune diseases.

The present invention provides protease variants, compositions comprising protease variants, and methods of using such protease variants and compositions.

A composition that can activate both a class B and class C G-protein-coupled receptor (GPCR) simultaneously is described herein. This composition can be used in a variety of methods, and is exemplified by a HYBD-HEXA peptide, which is found in SEQ ID NO: 1.

A method for generating binding peptides presented by any given Major Histocompatibility Complex (MHC) protein is presented. The method includes, given a peptide and an MHC protein pair, enabling a Reinforcement Learning (RL) agent to interact with and exploit a peptide mutation environment by repeatedly mutating the peptide and observing an observation score of the peptide, learning to form a mutation policy, via a mutation policy network, to iteratively mutate amino acids of the peptide to obtain desired presentation scores, and generating, based on the desired presentation scores, qualified peptides and binding motifs of MHC Class I proteins.

The application describes ceDNA vectors having linear and continuous structure for delivery and expression of a transgene. ceDNA vectors comprise an expression cassette flanked by two ITR sequences, where the expression cassette encodes a transgene encoding FVIII protein. Some ceDNA vectors further comprise cis-regulatory elements, including regulatory switches. Further provided herein are methods and cell lines for reliable gene expression of FVIII protein in vitro, ex vivo and in vivo using the ceDNA vectors. Provided herein are method and compositions comprising ceDNA vectors useful for the expression of FVIII protein in a cell, tissue or subject, and methods of treatment of diseases with said ceDNA vectors expressing FVIII protein. Such FVIII protein can be expressed for treating disease, e.g., hemophilia A.

Disclosed are protein switches, components of such protein switches, and uses thereof, which can sequester biologically active peptides and / or binding domains, keeping them in an inactive ("off") state until combined with a second, designed polypeptide, termed a key, thereby inducing a conformational change that activates ("on") the biologically active peptide or binding domain.

Described herein are engineered proteins and methods of use of such proteins. Also described herein are complexes, compositions, and systems comprising the engineered proteins of the invention, each of the complexes, compositions, and systems can be used to modify and / or edit a target nucleic acid. The engineered proteins of the invention may be enzymes, and / or may be RNA-guided DNA binding proteins.

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.

CD3-binding proteins, CDR sequences, variable domain sequences, and related compositions, and methods for their use and manufacture.

The present disclosure relates to formulations comprising a protein comprising an Fc region (e.g., an antibody) and a surfactant such as a polysorbate (e.g., Polysorbate 20), and methods of purifying such proteins that improve stability of the surfactant such as a polysorbate in such formulations.

The present invention generally relates to improved protease-activatable antigen-binding molecules. The protease-activatable antigen-binding molecules contain an anti-idiotypic binding portion that reversibly masks the CD3 antigen-binding portion of the molecule. Furthermore, the present invention relates to polynucleotides encoding such protease-activatable T cell binding molecules, as well as vectors and host cells containing such polynucleotides. The present invention further relates to methods for producing the protease-activatable T cell binding molecules of the present invention and methods for using the protease-activatable T cell binding molecules, for example, in the treatment of diseases.

Provided herein are proteins, which are capable of being transported across the blood- brain barrier (BBB) and comprise an acid alpha-glucosidase (GAA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat Pompe disease.

A hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

Large scale produced water-soluble legume proteins and obtained by: Crushing legume seeds, if necessary, degreasing the crushed legume seeds; Mixing the crushed legume seeds with water to produce a legume slurry; Adjusting the pH value of the legume slurry to a pH value between 6.8 and 7.5, preferably between 7.0 and 7.4; Separating starch and fibers by centrifugation or filtration to produce an aqueous protein solution as supernatant; Adjusting the pH value of the separated protein solution to a pH value between 7.2 and 8, Ultrafiltrating the pH-adjusted protein solution; Diafiltrating the ultrafiltration retentate with water with a pH value of 7.5-8.2 to a conductivity of the diafiltrate of no more than 30% of the conductivity of the permeate without diafiltration, i.e., to a conductivity of 1-3 mS / cm; Obtaining the diafiltered ultrafiltration protein retentate; and drying, cooling or freezing the ultrafiltration retentate, and a method for its production.

The invention discloses a dipeptide modified polymer and application thereof in intracellular delivery of protein. The screened polymer and protein form a compound and are subjected to phase transformation, solute in a liquid phase is transformed into solid-phase particles insoluble in water, early release of the target protein is reduced, and delivery of the protein in the presence of serum is achieved. The protein intracellular delivery method provided by the invention has relatively high intracellular delivery efficiency in the presence of serum-free protein and serum, and the delivery efficiency is higher than that of a commercial protein transfection reagent PULSin; after beta-Gal and other enzyme proteins are delivered into cells, the activity can be recovered, a catalytic substrate is converted into a monitorable product, and the amount of the delivered and active recovered protein is less affected by serum protein in incubation conditions; in addition, the material has low cytotoxicity, the cell activity is higher than 90% under the experimental condition of protein delivery, and the material has good biocompatibility.

The present application relates to ANXA3 protein targeted degradation chimera and its preparation method and application. Specifically, the present application relates to ANXA3 protein targeted degradation chimera, or its pharmaceutically acceptable salt, or its stereoisomer, or a pharmaceutical composition composed of a medically acceptable carrier, and the use in preparing ANXA3 protein targeted degradation chimera and the use in preparing drugs for preventing and / or treating breast cancer. The present application utilizes the PROTAC technology to provide a kind of ANXA3 protein targeted degradation chimera, which can combine ANXA3 protein, selectively degrade ANXA3 protein, inhibit the proliferation of breast cancer cells in vitro, and play the role of anti-breast cancer. Breast cancer refers to breast cancer molecular subtypes such as triple negative, Luminal A type, Luminal B type, Her2+ type.

Immunoglobulin complementarity determining regions ("CDRs"), and immunoglobulin binding domains comprising those CDRs, that bind human lymphocyte antigen 6 family member G6D (LY6G6D), and their use for the preparation of LY6G6D-binding proteins finding use as immunotherapeutics.

The present invention provides novel markers of the severity of a central nervous system injury, such as spinal cord injury or traumatic brain injury, in a patient. In particular, protein components of inflammasomes in the cerebrospinal fluid that can be used to assess the severity of central nervous system injury in a patient are disclosed. Methods of using such protein biomarkers to determine a prognosis, direct treatment and rehabilitation efforts, and monitor response to treatment for a patient with a central nervous system injury are also described.

This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and / or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay). Such predictive assays could for example be used to test whether a given ISV could have a tendency to give rise to such protein interference and / or such a signal; to select ISV's that are not or less prone to such protein interference or to giving such a signal; as an assay or test that can be used to test whether certain modification(s) to an ISV will (fully or partially) reduce its tendency to give rise to such interference or such a signal; and / or as an assay or test that can be used to guide modification or improvement of an ISV so as to reduce its tendency to give rise to such protein interference or signal; —methods for modifying and / or improving ISV's to as to remove or reduce their tendency to give rise to such protein interference or such a signal; —modifications that can be introduced into an ISV that remove or reduce its tendency to give rise to such protein interference or such a signal; ISV's that have been specifically selected (for example, using the assay(s) described herein) to have no or low(er) / reduced tendency to give rise to such protein interference or such a signal; modified and / or improved ISV's that have no or a low(er) / reduced tendency to give rise to such protein interference or such a signal.

The invention relates to the technical field of spreading modes of human viruses, in particular to a virus spreading mode prediction model based on interaction of virus protein and human protein, a prediction model construction method and a prediction method. The method specifically comprises the following steps: S1, constructing a training data set of a virus transmission mode; s2, based on the data in the S1, obtaining a virus-human protein interaction prediction result, vectorizing the prediction result by using 0 / 1 coding, and constructing a virus-human protein interaction matrix; and S3, using a machine learning algorithm and a feature selection project to construct and train a virus propagation mode prediction model based on the interaction of the virus protein and the human protein. The method for predicting the virus propagation mode of interaction between the virus protein and the human protein is convenient to use and wide in application range; the method is especially suitable for new viruses or unknown viruses which are not fully researched, and can realize efficient and rapid propagation mode identification.

The invention discloses judgment and optimization of key amino acid sites for controlling sesquiterpene synthesis, and determines amino acid residues lysine or arginine or glutamine related to sesquiterpene synthesis for point mutation and combined mutation of various plant sesquiterpene synthase. Lysine or arginine or glutamine is located in a cavity among 5-10 amino acids in front of the first long alpha helix at the N end, alpha helixes (also the longest alpha helix in the protein) communicating the N end and the C end of the protein and the last 1-7 amino acids at the C end at the site. The method for determining the key amino acid can be used for efficiently screening the sesquiterpene synthase with activity, and the optimization of the amino acid of the key residue can be used for guiding the transformation of the high-yield sesquiterpene synthase for industrial production. The invention has important application value and economic benefit in the fields of biological synthase identification of sesquiterpenoids, biosynthesis of drugs, fermentation production of spices, synthesis of industrial raw materials and the like.

Proteases may include an amino acid sequence having at least 70% sequence identity with the amino acid sequence given in SEQ ID NO:1 over its entire length. The proteases may further have, in each case based on the numbering according to SEQ ID NO:1, amino acid substitutions 9T, 130D / V, 133A, 144K, 217M, 252T and 271E at the positions corresponding to positions 9, 130, 133, 144, 217, 252 and 271. The proteases may further include at least one further amino acid substitution at at least one of the positions corresponding to positions 6, 89, 131, 166, 189, 211 or 224, and to the production and use thereof. Such proteases exhibit very good stability with good cleaning performance.